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Although amorphous silica nanoparticles are widely used in the production of food products (e.g., as anticaking
agents), there is little information available about their absorption and biological effects after oral exposure. Here, we
examined the in vitro intestinal absorption and in vivo biological effects in mice of orally administered amorphous
silica particles with diameters of 70, 300, and 1,000 nm (nSP70, mSP300, and mSP1000, respectively) and of nSP70
that had been surface-modified with carboxyl or amine groups (nSP70-C and nSP70-N, respectively). Analysis of
intestinal absorption by means of the everted gut sac method combined with an inductively coupled plasma optical
emission spectrometer showed that the intestinal absorption of nSP70-C was significantly greater than that of
nSP70. The absorption of nSP70-N tended to be greater than that of nSP70; however, the results were not statistically
significant. Our results indicate that silica nanoparticles can be absorbed through the intestine and that particle
diameter and surface properties are major determinants of the degree of absorption. We also examined
the biological effects of the silica particles after 28-day oral exposure in mice. Hematological, histopathological,
and biochemical analyses showed no significant differences between control mice and mice treated with
the silica particles, suggesting that the silica nanoparticles evaluated in this study are safe for use in food
production.
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Nanomaterials are currently used in a variety of applica-
tions, including the production of food products. For
example, amorphous silica nanoparticles are widely used
as stabilizers, anticaking agents, and carriers for fragrances
and flavors [1-3]. With the growing commercialization of
nanomaterial-derived food additives, the opportunities for
human oral exposure to nanomaterials are substantially
increasing; however, there have been few studies conduc-
ted, examining the safety of nanomaterials in food products.
Therefore, assessments of the absorption and biological
effects of nanomaterials after oral exposure are urgently
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in any medium, provided the original work is pThe information currently available about the biological
effects and absorption of nanomaterials after oral exposure
is limited. For example, 56-nm silver nanoparticles have
been found to be distributed in rat liver, kidney, brain,
lung, and blood after 90 days of oral exposure at doses of
30, 125, or 500 mg/kg, and a no-observed-adverse-effect
level (NOAEL) of 30 mg/kg and a lowest-observed-ad-
verse-effect level (LOAEL) of 125 mg/kg have been sug-
gested for these nanoparticles [4]. However, there is little
information about the intestinal absorption and biological
effects of silica nanoparticles after oral exposure. Further-
more, an efficient method to determine the absorption of
silica particles in the human body is yet to be established.
Therefore, to evaluate the safety of silica nanoparticles
after oral exposure, practical in vitro methods that allow
prediction of the in vivo intestinal absorption and biological
effects of silica nanoparticles after long-term oral exposure
are urgently needed.an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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the in vitro absorption and intestinal metabolism of drugs.
This method, which was first described by Wilson and
Wiseman in 1954 and then later improved by Barthe
et al., has been extensively used to investigate the pharma-
cokinetics of drug absorption, drug metabolism, and pro-
drug conversion in gastrointestinal segments [5-7]. This
method has also recently been used to obtain information
about the absorption of drugs contained in nanocarriers
such as liposomes [8]. The results of these studies suggest
that this method could be used to accurately measure the
intestinal absorption of silica nanoparticles.
In the present study, we used the everted gut sac
method to evaluate the intestinal absorption of amorph-
ous silica particles of various diameters. In addition, we
investigated the in vivo biological effects of 28-day oral
administration of the amorphous silica particles in mice.
Methods
Silica particles
We evaluated the following particles purchased from
Micromod Partikeltechnologie, Rostock/Warnemünde,
Germany: amorphous silica nanoparticles (nSP) with a
diameter of 70 nm (nSP70), microsilica particles (mSP) with
diameters of 300 or 1,000 nm (mSP300 and mSP1000,
respectively), and nSP70 that had been surface-modified
with carboxyl or amine groups (nSP70-C and nSP70-N,
respectively). All the silica particles were sonicated for
5 min and vortexed for 1 min prior to use.
Animals
BALB/c mice (female, 6 weeks) were purchased from Japan
SLC (Shizuoka, Japan) and Wister rats (male, 8 weeks)
were purchased from Shimizu Laboratory Supplies Co
(Kyoto, Japan). The animals were housed separately in a
ventilated animal room that was maintained at 20°C ± 2°C
under a 12-h light/12-h dark cycle. All the animal experi-
ments in this study were performed in accordance with the
National Institute of Biomedical Innovation and the Osaka
University Guidelines for the Welfare of Animals.
Everted gut sac analysis
Wistar rats (male, 8 weeks) were fasted for 12 h (ad libi-
tum access to water) prior to the experiment. The rats
were anesthetized with pentobarbital, subjected to abdom-
inal section, and exsanguinated by transection of the
descending aorta. The whole small intestine was isolated
and gently flushed with Tyrode’s buffer (NaCl, 137 mM;
KCl, 5.4 mM; NaH2PO4, 0.16 mM; MgCl2, 0.5 mM; CaCl2,
1.8 mM; HEPES, 5 mM; pH 7.4). A 3- to 4-cm segment
of the small intestine was removed and everted over a
silicone tube. The bottom portion was tied with thread
and the segment was filled with 0.6 to 0.8 mL of Tyrode’s
buffer. The filled segment was then placed in 2.5 mL ofTyrode’s buffer only (control group) or a solution of silica
particles (12.5 mg/mL) in Tyrode’s buffer or/and incu-
bated at 37°C for 45 min. After incubation, the solution
on the serosal side of the segment was collected. An in-
ductively coupled plasma optical emission spectrometer
(ICP-OES; 735-ES, Agilent Technologies, Tokyo, Japan)
was used to determine the silicon content in the solution.
Oral exposure of mice to silica particles
BALB/c mice (female, 6 weeks) were orally exposed to
nSP70, mSP300, mSP1000, nSP70-C, nSP70-N, or water
(control group) at a daily dose of 2.5 mg/mouse adminis-
tered by means of oral gavage for 28 days. The mice were
weighed on days 7, 14, 21, and 28 of the study period.
Blood biomarker assay
Twenty-four hours after the final oral administration of
the silica particles, a blood sample was collected from
the heart of each mouse by means of a plastic syringe
containing 5 IU/mL of heparin sodium. Plasma was har-
vested by centrifuging the collected blood at 1,750 × g
for 15 min. The plasma levels of alanine aminotransferase
(ALT) and blood urea nitrogen (BUN) were determined
with a biochemical auto-analyzer (Fuji Dri-Chem 7000,
Fujifilm, Tokyo, Japan).
Histopathological examination
Twenty-four hours after the final oral administration of
the silica particles, the liver, kidney, brain, lung, spleen,
heart, stomach, small intestine, or large intestine of the
mice were excised and fixed immediately in 4% para-
formaldehyde. The tissues were embedded in paraffin
blocks and sectioned, and the sections were mounted on
glass slides.
Hematological analysis
Twenty-four hours after the final oral administration of
the silica particles, a blood sample was collected from the
heart of each mouse by means of a plastic syringe contain-
ing 0.1 mM EDTA, and the numbers of total white blood
cells, lymphocytes, monocytes, red blood cells, granulo-
cytes, and platelets in whole blood were determined with
an auto-analyzer (VetScan HMII Hematology System,
Abaxis, Sunnyvale, CA, USA).
Statistical analysis
Differences between the treated groups and the control
groups were compared with Tukey’s test after analysis of
variance.
Results
Physicochemical properties of silica particles
Previously, we confirmed by means of dynamic laser scat-
ter analysis that the mean secondary particle diameters of
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322, 1,140, 70, and 72 nm, respectively [9]. Transmission
electron microscopy revealed that the silica particles are
well-dispersed smooth-surfaced spheres, indicating that
they remain stable and well dispersed in solution and do
not aggregate [9].
Intestinal absorption of silica particles
We used the everted gut sac method to evaluate the
intestinal absorption of silica particles. Tissue viability is
a limiting factor in everted gut sac analysis; however, the
viability and metabolic activity of intestinal tissue has
been reported as being retained for approximately 2 h
under physiological conditions [10]. Everted gut sac ana-
lysis revealed that the absorption of nSP70-C and nSP70-
N from the mucosal side to the serosal side of the sacs
was significantly greater than the absorption of the other
silica particles after incubation for 45 min. And the ab-
sorption of nSP70-C was significantly greater than that of
nSP70 (Figure 1). This suggested that silica nanoparticles
are absorbed through the intestine and that the surface
property of the particles is one of a determinant of the
degree of absorption.Figure 1 Measurement of the absorption of silica particles
using everted gut sac method. Measurement of the absorption of
silica particles in rat intestine by means of the everted gut sac
method combined with an inductively coupled plasma optical
emission spectrometer. Intestinal sacs were incubated in solutions of
the indicated silica particles (12.5 mg/mL) for 45 min. Values are
expressed as mean ± SD (n = 5 to 12). *P < 0.01 and **P < 0.05
compared with the control group.Biological effects of silica particles
Oral exposure of BALB/c mice to nSP70, mSP300,
mSP1000, nSP70-C, and nSP70-N at 2.5 mg/mouse for
28 days produced no significant differences in body weight
in the treated mice compared with in the control mice
(Figure 2A). We observed no significant changes in the
plasma levels of ALT (marker of liver function) or BUN
(sensitive indicator of kidney damage) after oral adminis-
tration of the silica particles in treated mice compared
with control mice (Figure 2B,C). Although ALT values of
silica nanoparticle-treated group are slightly higher than
control group, the change of the ALT value was within
healthy range (the range was about below 43 U/L) among
all the groups. Therefore, we speculate that the level of
ALT among all the groups does not effect on liver’s func-
tion. Histopathological examination revealed no abnor-
malities in the liver, kidney, and large intestine (Figure 3)
or any other tissue (the brain, lung, spleen, heart, stomach
and small intestine; data not shown) in the treated mice.
Furthermore, the counts of total monocytes, granulocytes,
or platelets in the treated mice were also not significantly
different from those in the control mice (Figure 4). Al-
though the white blood cells, lymphocytes, and the red
blood cell counts in the treated mice were significantly
different from those in the control group, they were within
the normal, healthy range or slightly increase (the white
blood cells: 6 to 15 × 109/L, lymphocytes: 3.7 to 7.4 ×
1012/L, red blood cells: 7 to 12 × 1012/L) in all groups
(Figure 3A,B,F). Taken together, our results indicate that
oral administration of nSP70, mSP300, mSP1000, nSP70-C,
or nSP70-N for 28 days does not produce any abnormal
biological effects, suggesting that the silica nanoparticles
tested are safe for use in food production.
Discussion
In the present study, we attempted to quantify the
absorption of silica particles by using ICP-OES to measure
the silicon content in the liver and blood after 28-day oral
exposure. However, we did not detect the silicon content
in the biological tissue with this analytical protocol (data
not shown; detection limit of the protocol, 0.1 μg). ICP-
OES protocols are regarded to be suitable for measuring
silica; however, our attempt to measure ultratrace levels
of the silicon content derived from silica particles may
have been hindered by interference from nitrogen present
in the air. Other groups have also been unable to deter-
mine the level of the silicon content derived from with
ICP-OES after oral exposure because of interference [11].
We therefore tried to measure the absorption of silica par-
ticles through the intestine by means of a combination of
the everted gut sac method and ICP-OES. The advantages
of this model are that there is a relatively large surface
area available for absorption and that a mucus layer is
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Figure 2 Body weight, histopathological, and biochemical analyses after 28-day oral administration of the indicated silica particles.
(A) Body weight during 28-day oral administration of silica particles; plasma concentrations of (B) alanine aminotransferase (ALT) and (C) blood
urea nitrogen (BUN). Values are expressed as mean ± SE (n = 4 to 11).
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and the absorption of nSP70-C was also significantly
higher than that of nSP70 (Figure 1). This indicates that
the differences in intestinal absorption of nSP70-C and
nSP70-N may be a result of the particles being absorbed
via different proteins. Indeed, some groups have suggested
that interactions between proteins and nanomaterials play
important roles in the biological effects and biodistribution
of nanomaterials [12]. In the future, to understand the
mechanism of intestinal absorption, we will need to exam-
ine the relationships between intestinal absorption and
the binding proteins of nSP70, nSP70-C, and nSP70-N.
We found that the everted gut sac method was effective
for assessing the intestinal absorption of nanomaterials.
Although the relationship between models of in vivo
absorption and the everted gut sac model of in vitro
absorption must be further elucidated, we expect our
results to contribute to the development of methods
for determining the absorption of silica particles after
oral exposure.We next exposed BALB/c mice to silica particles at
an oral dose of 2.5 mg/mouse, which is approximately
10 times the upper safe limit for consumption of silica by
adult humans set by the United Kingdom Food Standards
Agency’s Expert Group on Vitamins and Minerals (700 mg
silica/day) [13]. Since silica nanoparticles are already used
as food additives in some food products, for example,
coffee creamer (silica nanoparticle content, 1.0 g/kg) and
instant soup [1], we consider the dose used in the present
study (2.5 mg/mouse) to be high enough for the evalu-
ation of the biological effects of oral administration of the
particles. Histopathological, biochemical, and hematolo-
gical analyses showed no differences between the treated
mice and the control mice (Figures 2, 3, and 4). How-
ever, another research group has reported that silica
nanoparticles (diameter, 30 nm) have toxic effects on
the liver when administered orally at a total dose of
140 g/kg over 10 weeks [14], which is a dose approxi-
mately 20 times that used in the present study. Therefore,
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Figure 3 Histopathological analysis after 28-day oral administration of the indicated silica particles. (A to F) liver, (G to L) kidney,
(M to R) large intestine.
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elucidated.
Our previous study showed that intravenous or intra-
cutaneous administration of silica nanoparticles caused
pregnancy complications [9] and modulation of the im-
mune response [15]. Furthermore, it is possible that
intranasally administered silica nanoparticles induce
abnormal activation of the coagulation system and modu-
late the immune response [16,17]. Therefore, in which
tissues silica nanoparticles localize after oral exposure,as well as their chronic, reproductive, and immune
toxicities, should be determined by using an oral expos-
ure model.
Conclusions
By using the everted gut sac method coupled with
ICP-OES, we examined the intestinal absorption of silica
particles and found that surface properties were major
determinants of the degree of intestinal absorption.




Figure 4 Hematological analysis after 28-day oral administration of the indicated silica particles. Hematological analysis of (A) white
blood cells, (B) lymphocytes, (C) monocytes, (D) granulocytes, (E) platelets, and (F) red blood cells. Values are expressed as mean ± SE
(n = 4 to 11). *P < 0.01 and **P < 0.05 compared with the control group; † P < 0.05 compared with the nSP70 group, as indicated by
Tukey’s test.
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suggest that the everted gut sac method coupled with
ICP-OES could be one of the effective methods for
assessing the absorption of silica particles. The results
of this study will be useful for the development of methods
for assessing the safety of silica nanoparticles and for the
creation of safer nanoparticles.
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